ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 161 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2018. The put-call ratio across all filers is 3.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $141,447,000 | -9.4% | 3,522,964 | +3.8% | 3.56% | -28.9% |
Q4 2018 | $156,076,000 | +7.1% | 3,392,964 | +3.4% | 5.00% | +29.7% |
Q3 2018 | $145,665,000 | +16.8% | 3,282,964 | +3.1% | 3.86% | +7.0% |
Q2 2018 | $124,740,000 | -28.5% | 3,182,964 | +31.9% | 3.60% | -25.3% |
Q1 2018 | $174,530,000 | +12.2% | 2,412,964 | +2.1% | 4.82% | +10.1% |
Q4 2017 | $155,578,000 | +48.0% | 2,362,964 | +12.6% | 4.38% | +50.5% |
Q3 2017 | $105,150,000 | +50.1% | 2,097,964 | +38.6% | 2.91% | +36.0% |
Q2 2017 | $70,047,000 | +40.8% | 1,513,542 | +7.5% | 2.14% | +31.6% |
Q1 2017 | $49,736,000 | +203.6% | 1,408,542 | +7.6% | 1.63% | +168.0% |
Q4 2016 | $16,383,000 | -9.6% | 1,308,542 | 0.0% | 0.61% | -4.7% |
Q3 2016 | $18,123,000 | +81.9% | 1,308,542 | +29.7% | 0.64% | +62.1% |
Q2 2016 | $9,964,000 | -41.6% | 1,008,542 | 0.0% | 0.39% | -42.0% |
Q1 2016 | $17,054,000 | -15.7% | 1,008,542 | +11.0% | 0.68% | +18.9% |
Q4 2015 | $20,224,000 | -5.6% | 908,542 | 0.0% | 0.57% | -16.2% |
Q3 2015 | $21,433,000 | – | 908,542 | – | 0.68% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $27,840,842 | 18.82% |
Ikarian Capital, LLC | 1,891,147 | $11,781,846 | 2.84% |
Altium Capital Management LP | 620,000 | $3,862,600 | 1.96% |
Ikarian Capital, LLC | 1,296,900 | $8,079,687 | 1.95% |
Parkman Healthcare Partners LLC | 822,784 | $5,125,944 | 1.36% |
Deep Track Capital, LP | 4,000,000 | $24,920,000 | 1.05% |
Monaco Asset Management SAM | 470,100 | $2,928,723 | 0.88% |
BRAIDWELL LP | 3,393,405 | $21,140,913 | 0.71% |
Telemetry Investments, L.L.C. | 71,000 | $442 | 0.70% |
Rhenman & Partners Asset Management AB | 900,000 | $5,607,000 | 0.58% |